Veterinary pharmacovigilance. Part 2. Veterinary pharmacovigilance in practice -- the operation of a spontaneous reporting scheme in a European Union country -- the UK, and schemes in other countries.
Veterinary pharmacovigilance, as it operates in the European Union (EU), covers a very broad remit, including adverse effects in treated animals, exposed humans and the environment, and in addition, it extends to cover the violation of maximum residue limits. The mainstay of veterinary pharmacovigilance is the spontaneous reporting scheme working along side other systems such as those reporting on residues surveillance. One of the most well established schemes in the EU is that operating in the UK and this paper examines the evolution of that scheme and some of its findings, data from other countries, and information available from the literature. It also tentatively examines the ways that pharmacovigilance can be used for regulatory purposes, and the contribution from pharmacoepidemiology.
Woodward
K N
KN
Schering-Plough Animal Health, Uxbridge, Middlesex, UK. kevin.woodward@spcorp.com
D016907:Adverse Drug Reaction Reporting Systems / Q000458:organization & administration*; D000818:Animals; D005062:European Union; D006801:Humans; D006113:United Kingdom; D019155:Veterinary Drugs
D019155:Veterinary Drugs